Relevant conflicts of interest/financial disclosures: Sylvain Chouinard has consulted and served on the advisory board of Teva, AbbVie, Novartis, UBC and Allergan and has received honoraria from Teva, AbbVie, Novartis and UBC. Geneviéve Bernard has served as a consultant for Actelion Pharmaceuticals.
A treatable new cause of chorea: Beta-ketothiolase deficiency
Article first published online: 1 JUL 2013
© 2013 Movement Disorder Society
Volume 28, Issue 8, pages 1054–1056, July 2013
How to Cite
Buhaş, D., Bernard, G., Fukao, T., Décarie, J.-C., Chouinard, S. and Mitchell, G. A. (2013), A treatable new cause of chorea: Beta-ketothiolase deficiency. Mov. Disord., 28: 1054–1056. doi: 10.1002/mds.25538
Full author roles may be found in the Acknowledments section online.
- Issue published online: 12 AUG 2013
- Article first published online: 1 JUL 2013
- Manuscript Accepted: 27 MAR 2013
- Manuscript Revised: 18 FEB 2013
- Manuscript Received: 5 OCT 2012
Options for accessing this content:
- If you have access to this content through a society membership, please first log in to your society website.
- If you would like institutional access to this content, please recommend the title to your librarian.
- Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
- You can purchase online access to this Article for a 24-hour period (price varies by title)
- New Users: Please register, then proceed to purchase the article.
Login via OpenAthens
Search for your institution's name below to login via Shibboleth.
Registered Users please login:
- Access your saved publications, articles and searches
- Manage your email alerts, orders and subscriptions
- Change your contact information, including your password
Please register to:
- Save publications, articles and searches
- Get email alerts
- Get all the benefits mentioned below!
Patients and/or caregivers may access this content for use in relation to their own personal healthcare or that of a family member only. Terms and conditions will apply.